Evidence map›Paper›PMID 40917788›Full record

ArticleImmune network2025

Pathotype-Specific Expression of Granzyme-Perforin Pathway Genes and Their Association With Clinical Disease Activity in Early Rheumatoid Arthritis and in a Randomized Clinical Trial.

Francisco G La Rosa, Larry W Moreland, Luigi Nibali, Mike Curtis, Kevin D Deane, Colin Strickland, Jennifer Seifert, Carson Keeter, Dmitri Simberg, Robert I Scheinman and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immune network, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Francisco G La RosaDepartment of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-4989-3001
Larry W MorelandDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0003-4483-0359
Luigi NibaliCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London Guy's Hospital, London SE1 9RT, UK.ORCID https://orcid.org/0000-0002-7750-5010
Mike CurtisCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London Guy's Hospital, London SE1 9RT, UK.ORCID https://orcid.org/0000-0002-1563-9953
Kevin D DeaneDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0001-5421-9815
Colin StricklandDepartment of Radiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-3778-8845
Jennifer SeifertDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0001-5851-7246
Carson KeeterDepartment of Orthopedics and the Colorado Program for Musculoskeletal Research, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0009-0001-2709-7338
Dmitri SimbergDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, CO 80045, USA.ORCID https://orcid.org/0000-0002-5288-6275
Robert I ScheinmanDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, CO 80045, USA.ORCID https://orcid.org/0000-0001-8485-6620
Rachel LauCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London E1 4NS, UK.ORCID https://orcid.org/0000-0002-8330-8048
Costantino PitzalisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London E1 4NS, UK.ORCID https://orcid.org/0000-0003-1326-5051
Myles J LewisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London E1 4NS, UK.ORCID https://orcid.org/0000-0001-9365-5345
V Michael HolersDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-5634-7746
Nirmal K BandaDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-5291-5136
Accelerating Medicines Partnership RA/SLE Network

Funding

The Alternative Complement Pathway and Hemocompatibility of NanosurfacesR01AI154959 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Dmitri Simberg · 2020 to 2026
$3.5M
NIAID NIH HHS R01 AI154959
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease. We examined gene expression of five granzymes (GZMs), perforin (PRF-1), and serglycin (SRGN) from tissues derived from pathobiology of early arthritis cohort (PEAC) and phase 4 randomized controlled trial in anti-TNF inadequate responder patients with RA (R4RA). Information regarding gene expression of

Indexed as

Bulk RNA-seqEarly rheumatoid arthritisGranzymesPerforinSerglycinSynovium

Identifiers

PMID40917788
PMCPMC12411107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.